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Purpose: RNA and DNA sequencing data are traditionally used to discern intrinsic
cellular pathways in cancer pathogenesis, their utility for investigating the tumor microenvironment (TME) has not been fully explored. This study explores the use of sequencing
data to investigate immunity within the TME.
experimental design: Here, we use immune cell fraction estimation analysis to determine the immune profiles in the microenvironment of neuroblastoma (NB) based on
RNA-seq data in the TARGET database. The correlation between immune cell transcripts
and prognosis in pediatric NB is also investigated.
results: In silico analysis revealed a strong inverse correlation between MYCN amplification and leukocyte infiltration. This finding was validated by immunohistochemistry
analysis in tumor samples. Moreover, the abundance of CD4 T cells strongly associated
with better patient survival regardless of MYCN gene amplification, while those of CD8
T cells, NK or B cells do not. Based on characteristic cytokine expression of CD4 subsets
in tumors, the Th2 rather than Th1 levels were associated with better prognosis.
conclusion: We found that the in silico analysis of TARGET database reflected tumor
immunity and was validated by the immunohistochemical tumor data. Our results reveal
the association of MYCN amplification with repressed cellular immunity and the potential prognostic value of infiltrating CD4 T cell transcripts in pediatric NB. This analysis
illustrates the potential role of MYCN in NB as a regulator of immune privilege and
characterizes the power of in silico analysis for delineating cancer immunology and risk
stratification.
Keywords: MYCN, immunesuppression, neuroblastoma, cellular immunity, in silico analysis

INTRODUCTION
Neuroblastoma (NB) is among the most common cancers in childhood. More than 90% of NB
are diagnosed prior to 5 years of age, in which the prognosis of NB varies greatly based on risk
stratification (1–3). While >90% of patients with intermediate and low-risk tumors survive 5 years
or more, only 40–50% of patients with high-risk NB achieve 5-year survival (4). Risk stratification
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risk assignment, and MYCN-amplification status. The demo
graphy, risk stratification of NB with or without MYCN amplification were summarized in Table 1.

is based on genetic alterations, histological findings as well as age
of diagnosis among other clinical factors. While MYCN amp
lification and unbalanced 11q aberration have emerged as the
dominant factors in risk assignment (5), poorly differentiated
or undifferentiated ganglioneuroblastoma, and NB without these
genetic alterations can also show poor prognosis. It is therefore
of interest to search for other shared features of high-risk NB
identified by either histology or genetic risk profiles.
The theory of immune surveillance, as originally proposed by
Burnet, predicts that immune response is a key determinant of
cancer risk (6). In a 1972 study of histologic lymphocytic infiltration in 23 primary NBs, a positive correlation with survival
was found in infancy and childhood (7). Through extensive
investigations, it is established in a number of other tumor types
that components of immune infiltration into the tumor plays
a critical role in cancer prognosis. However, these analyses are
difficult to standardize, thus it has not been feasible to use them
as markers for risk assignment in cancer prognosis.
Whole genome sequencing of tumor samples is now routinely
performed for cancer samples. The wealth of data collected from
these studies allows one to unveil molecular pathogenesis of
cancer cells. Since host inflammatory cells are now considered
an integral part of the tumor microenvironment (TME), it is
inevitable that deep sequencing of cancer tissues will also capture
information of inflammatory cells. CIBERSORT is a recently
reported computational approach that uses gene expression
profiles to estimate relative fractions of diverse cell subsets in
complex tissues, including tumors (8, 9). The power of this
algorithm in delineating immune composition of tumor tissues
prompted us to test whether one can use the bulk of next generation sequencing data already collected to evaluate the potential
role of immunity in determining prognosis in NB, a tumor with
well-defined risk stratification. Here, we report our use of this
program to analyze TARGET data matrix for NB in which we
found that CD4 T cell signature significantly associates with
prognosis of NB in both MYCN amplified and non-amplified
tumors. We also observed the unexpected association between
MYCN gene amplification and lack of inflammatory profiles
suggesting the impact of MYCN gene amplification in repressing NB host immunity. These findings were verified by selective
immunohistochemistry in patient samples. Furthermore, these
data show the power of in silico analysis for cancer immunology and raises the intriguing possibility of assigning cancer risk
based on nextgen RNA-seq data.

Immune Cell Fraction Estimation Analysis

The online analytic tool, CIBERSORT (Cell type Identification
By Estimating Relative Subsets Of known RNA Transcripts), was
used according to the instruction provided by the developers.2
LM22, a validated leukocyte gene signature matrix, was used
here as a gene signature matrix. LM22 contains 547 genes that
distinguish 22 human hematopoietic cell phenotypes. The gene
expression data from the NB patients in TARGET database
(n = 148) were input as a Mixture file and 500 permutations
were performed. The percentage data of 22 immune cell types
in each patient were transferred into the cell fraction of tumor
by normalization with the ratio of CD45 and ACTB expression
value. Additionally, 22 human hematopoietic cell phenotypes
were merged into 16 immune cell types as follows: naive and
memory B cells were merged into B cells; naïve, memory, resting,
and activated CD4 T cells were merged into CD4 T cells; NK cells
resting and NK cells activated were merged into NK cells; dendritic cells resting and dendritic cells activated were merged into
DC cells; while mast cells resting and mast cell activated were
merged into mast cells.

Stratification of Subgroups Based
on Expression and Fraction Data

For CD45 expression, the NB samples were divided into CD45hi
and CD45lo groups with the threshold (FPKM = 7.5) based
on its bimodal distribution of RNA-seq data (Figure S1A in
Supplementary Material). Gene expression levels were normalized based on actin expression and samples were divided into
higher ratio (above the upper quartile) and lower ratio (below
the lower quartile) groups based on RNA-seq data. For other
parameters, the samples were divided into lower cell fraction
(below the fraction value of peak) and higher cell fraction (above
the twofold of fraction value of peak) groups based on their data
2

Table 1 | Baseline characteristics of the patients.*
Characteristic

MATERIALS AND METHODS

Patients
without MYCN
amplification
(n = 117)

Statistical
significance
(P-value)

1,303.18 ± 101.853

ns (0.22)

69 (59.0)
48 (41.0)

ns (>0.99)
ns (>0.99)

COG risk group—no. (%)
High risk
31 (100.0)

91 (77.8)

Intermediate risk
Low risk

13 (11.1)
13 (11.1)

Significant
(0.0024)
ns (0.07)
ns (0.07)

Sex—no. (%)
Male
Female

The TARGET initiative provides sequencing data and deidentified clinical information of cancer patients (available
through the TARGET Data Matrix1). The current studies utilized
database of genotypes and phenotypes via accession phs000471.
A total of 148 NB patients were included based on availability
detailed RNA-seq FPKM data, survival time after diagnosis,

18 (58.1)
13 (41.9)

0 (0.0)
0 (0.0)

*P-values were calculated by using two-tailed Student’s t-test (age at diagnosis) and
Fisher’s exact test [sex and Children’s Oncology Group (COG) risk Group].

http://target.nci.nih.gov/dataMatrix/TARGET_DataMatrix.html.
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Patients with
MYCN amplification
(n = 31)

Age at diagnosis—days
Mean ± SEM
1,037.52 ± 162.672

Data Source

1
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distribution of estimated cell fraction (T cells CD4 cell fraction
distribution shown in Figure S1B in Supplementary Material).

blinded to the clinical stage or characteristics of the tumor specimen. Data are presented as the mean positive staining intensity
of all the fields for each specimen.

Gene Set Enrichment Analysis (GSEA)

Biostatistics

Gene set enrichment analysis version 2.3.03 was performed
with the JavaGSEA application using the following parameters:
number of permutations = 1,000, permutations of phenotype,
curated KEGG gene sets from MSigDB as gene sets database
input. Significant enrichment was defined as those lists with >30
genes and a false discovery rate <0.05.

The specific tests used to analyze each set of experiments are
indicated in the figure legends. Data were analyzed using an
unpaired Mann–Whitney test to compare between two groups,
and χ2 test for contingency table. In the graphs, y-axis error
bars represent SEM as indicated. Statistical calculations were
performed using GraphPad Prism software (GraphPad Software,
San Diego, CA, USA) or R Software.4

Specimens

Tumor specimens were obtained from 15 patients diagnosed
with low (n = 3), intermediate (n = 6), and high (n = 6) risk NB.
Diagnosis and staging were performed according to Children’s
Oncology Group protocols. Biopsies were taken at the time of
diagnosis and prior to initiation of any therapy. Specimen collection was obtained with the appropriate research consent
(and assents when applicable) and was approved by the Institu
tional Review Board, CNMC, Washington D.C. (Pro00004284).

RESULTS
MYCN Amplification Is Associated with
Reduced Inflammation in NB

To determine whether the increased risk is associated with
either reduced immune response or increased resistance to it,
we tested whether the inflammatory response is associated with
MYCN amplification among patients in the TARGET database.
The patients with or without MYCN amplification are similar
in age at diagnosis, gender distribution (Table 1). We chose the
transcript levels of the CD45 genes that is the marker for all leukocytes, among MYCN amplified or non-amplified NB tumors.
As shown in Figure 1A, after normalizing against ACTINB
transcripts, MYCN amplified NB had significantly lower levels
of CD45 transcripts, indicating reduced inflammation in MYCN
amplified NB. To determine whether MYCN affects specific
subset of leukocytes, we used the CIBERSORT algorithm to
estimate the percentage of each leukocyte subset, focusing on the
major cell types that can be identified by CIBERSORT. Among
the major immune effector cells, including T, B, macrophages,
dendritic cells, and NK cells, we found a general reduction of all
leukocytes in MYCN-amplified samples (Figure 1B). The strong
inverse correlation suggests that MYCN amplification in cancer
cells has a profound impact on host immune response to NB.
While poor prognosis MYCN-amplified NB is well accepted
and clearly demonstrable in the TARGET sample cohort
(Figure 2A), the risk of MYCN non-amplified samples is
traditionally stratified by a comprehensive list of clinical, pathological, and molecular criteria. To determine if the abundance
of CD45 transcripts can be used as a single parameter for NB
risk stratification in MYCN non-amplified NB, we evaluated
if CD45 levels associate with risk in this subgroup. As shown
in Figure 2B, samples with more abundant CD45 show better
survival, but the difference between CD45hi and CD45lo samples
was not statistically significant. The hazard ratio (HR) and
separation of the two groups suggest that lack of statistical
significance may be due to a limited number of CD45hi samples
as the TARGET samples are biased toward high-risk group
stratification. Combining MYCN non-amplification and CD45hi
parameters identified a group of NB patients with better survival
(HR = 0.49, P = 0.03) (Figure 2C).

Immunohistochemical Analysis

Five-micron paraffin tissue sections were deparaffinized in
xylene and rehydrated in 100 and 95% ethanol. Endogenous
peroxidase activity was blocked by treating with 0.3% hydrogen
peroxide for 30 min followed by phosphate-buffered saline (PBS)
washing for 5 min. Sections were incubated overnight at 4°C
with primary antibodies diluted in blocking buffer (PBS with
5% serum). The following primary antibodies were used: CD4
(rabbit monoclonal antihuman IgG, 1:150, abcam, Cambridge,
MA, USA); CD45 (mouse monoclonal antihuman IgG1, abcam).
Isotype-matched antibodies were used for negative controls.
After washing with PBS, each section was incubated with 1:200
diluted biotinylated secondary antibodies (Vector Laborato
ries, Inc., Burlingame, CA, USA) for 1 h at room temperature.
Secondary antibody was detected with Vectastain ABC reagent
(ABC Elite Kit; Vector Laboratories), and 3′3′diaminobenzidine
substrate (Sigma). Slides were washed in tap water for 5 min
and then counterstained with hematoxylin (Sigma) for 30 s.
Following counterstaining, slides were washed in tap water for
5 min, dehydrated (95 and 100% ethanol), transferred to 100%
xylene, and mounted. Brightfield immunohistochemical images
were acquired with a Nikon Eclipse E800 microscope (Nikon
Corp.). Images were taken at magnifications of ×100.

Quantitative Analysis of CD4 and CD45
Expression in Human Tissue

Thirty to forty randomly selected fields in each stained specimen were imaged under ×100 magnification. Quantification of
positive staining intensity was achieved using Olympus cellSens
imaging software (version 1.7). The positive staining intensity
and the area of tumor tissue were measured. The positive staining
intensity in each field was measured using a manual threshold
setting. Measurements were made by the same person who was
3

http://www.broadinstitute.org/gsea.
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Figure 1 | MYCN amplification in neuroblastoma (NB) affects inflammatory immune cell phenotypes. (A) MYCN-non-amplified NB samples had greater
inflammatory status as defined by CD45 expression (upper panel) and CD45/actin expression ratio (lower panel). (B) The relative abundance of six immune cell types
was greater in MYCN-non-amplified tumors than in MYCN-amplified tumors. Statistical significance in (A,B) was determined using Mann–Whitney test.

Figure 2 | Tumor inflammation, combined with MYCN amplification is associated with neuroblastoma (NB) prognosis. (A) Kaplan–Meier curves showing 5-year
survival of NB patients associated with MYCN amplification status. (B) Kaplan–Meier curves showing 5-year survival of NB patients assessed by CD45 expression.
CD45lo and CD45hi subgroups were defined based on FPKM distribution as detailed in Section “Materials and Methods.” (C) Kaplan–Meier curves showing 5-year
survival of NB patients according to the combination of MYCN amplification status and CD45 expression subtypes. The hazard ratio and P-value in (A,B,C)
displayed on the graphs are from the log-rank test and Gehan–Breslow–Wilcoxon method.

Abundance of CD4 T Cells in NB as a
Biomarker for Overall Survival

T cell subsets, we performed regression analysis of the transcript
levels for the CD4 and CD8 T cells. As shown in Figure 4A, the
levels of CD4 transcripts strongly correlated with the fraction
of CD4 T cells among all leukocytes. Likewise, the levels of
CD8 transcripts strongly associates with the CD8 cell fraction
(Figure 4B). To determine whether a specific leukocyte population may be associated with overall survival, we divided the
samples into high- and low-populations based on the relationship with peak values. Those below peak value are assigned as
the low subsets, while those that are 3-fold of the peak value are

As the first test to determine whether T cells play a significant
role in NB prognosis, we compared the overall survival of the
NB patients with the highest 25% or the lowest 25% levels of
the gene transcript. While the CD8Bhi and CD8Blo NB patients
show nearly identical overall survival (Figure 3A), the CD4hi
NB patients have significantly better survival (Figure 3B).
To confirm whether the abundance of CD4 or CD8B cell transcripts can be used as surrogate markers for the abundance of
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Figure 3 | CD4 gene expression in the tumor is the principal determinant of prognosis in all patients and in patients with MYCN non-amplified tumors.
(A) Kaplan–Meier curves showing 5-year survival of neuroblastoma (NB) patients according to their CD4 gene expression normalized to the ratio of actin
expression. Total NB samples (left) and MYCN non-amplified NB samples (right) were divided into CD4/ACTBhi (above the upper quartile) and CD4/ACTBlo (below
the lower quartile) groups based on RNA-seq data. (B) Kaplan–Meier curves showing 5-year survival of NB patients according to their CD8B gene expression
normalized with the ratio of actin expression. Total NB samples (left) and MYCN non-amplified NB samples (right) were divided into CD8B/ACTBhi (above the upper
quartile) and CD8B/ACTBlo (below the lower quartile) groups based on RNA-seq data. The hazard ratio and P-value in (A,B) displayed on the graphs are from the
log-rank test and Gehan–Breslow–Wilcoxon method.

Immunological Mechanism of Protection
by CD4 T Cells

defined as the high subset. As shown in Figure 4C, patients with
the CD4 T cellshi subsets in the tumor have much better overall
survival than those with the CD4 T cellslo subset. In contrast,
patients with the CD8 T cellshi subset had similar overall survival
to that of CD8 T cellslo subset (Figure 4D).
We performed selective immunohistochemistry analysis of
NB samples to confirm the key findings of the above in silico
analyses. As shown in Figures 5A,B, all MYCN-amplified
samples analyzed had minimal infiltration of CD4 T cells.
While high-risk MYCN non-amplified NB are similar in CD4
T cell infiltration, intermediate, and low-risk NB had variable
amounts of CD4 T cells infiltrates. As expected, the pattern of
CD45 staining is similar to the CD4 T cells (data not shown).
When the staining of CD45 and CD4 was integrated digitally,
it is clear that high-risk NB samples (including MYCN amplified and non-amplified) had reduced CD4 and CD45 staining
(Figure 5C). These data validated the in silico analysis.
Frontiers in Immunology | www.frontiersin.org

To understand the possible mechanism by which increased
CD4 T cells confer protection for NB patients, we performed
Kegg pathway analysis to identify enhanced pathway in the
samples in high-CD4 transcripts. The top 10 pathways are listed
in Figure 6A and examples of the association are shown in
Figure 6B. Chief among them include FcRγ-mediated phagocytosis, NK cell-mediated cytotoxicity, cell adhesion molecules,
and T cell signaling. These data suggest that CD4 T cells likely
promote cancer rejection by orchestrating innate immune effectors within the TME.
CD4 T cells can be divided into regulatory and effector
T cells. Since our preliminary analysis suggest no correlation
between Treg subsets (data not shown), we focused on effector
CD4 cells. CD4 T cells differentiated into multiple functional
subsets including Th0, Th1, Th2, Th9, and Th17 among others,

5
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Figure 4 | CD4 cell abundance is the principal determinant for prognosis in patients with MYCN non-amplified tumors. (A) Dot plot showing the correlations
between CD4 gene expression normalized with the ratio of actin expression and CD4 T cell relative abundance. (B) Dot plot showing the correlations between
CD8B gene expression normalized with the ratio of actin expression and CD8 T cell relative abundance. (C) Kaplan–Meier curves showing 5-year survival of
neuroblastoma (NB) patients with MYCN non-amplified tumors according to their CD4 T cell relative abundance. (D) Kaplan–Meier curves showing 5-year survival
of NB patients with MYCN non-amplified status according to their CD8 T cell relative abundance. NB samples were divided into Relative Abundancehi and Relative
Abundancelo groups, respectively, based on the immune cell relative abundance data as detailed in Section “Materials and Methods.”. Correlation coefficient and
P-value in (A,B) were determined using Spearman method. The hazard ratio and P-value displayed on the graphs are from the log-rank test and Gehan–Breslow–
Wilcoxon method.

Using in silico analysis from a sequence database, we investigated NB from the perspective of immune cell transcript
infiltrates and the association with outcome. It was clear that
CD4 transcripts were associated with better outcomes in which
a high transcript was associated with improved survival. This
correlated with immunohistochemistry for CD4 cellular infiltrates in which tumors with poor prognosis and high risk had a
lower CD4 cellular infiltrate in tumors. Though it is established
in a number of tumor types that components of immune infiltration into the tumor plays a critical role in cancer prognosis
(13–18), standardizing cellular infiltrates has been difficult and
thus application for risk stratification has not been practical.
Analyzing transcripts in sequence data may offer a method for
standardizing cellular infiltrates for use in risk assignment for
cancer prognosis.
MYCN amplification in NB is the most important molecular
biomarker categorizing tumors in the high-risk category. Irres
pective of all other clinical, molecular, or biomarkers, if MYCN
is amplified in the tumor it is categorized as high risk. In our
analysis, MYCN amplified NB had significantly lower levels of
CD45 transcripts, indicating reduced inflammation in MYCN
amplified tumors. All the transcripts of major immune effector
cells, including T cells, B cells, macrophages, dendritic cells,

each characterized by their cytokine profiles and their master
transcriptional regulators. Since most master regulators are
prominently expressed in cancer cells, we decide to use their
characteristic cytokines to discern the functional subsets associated with NB prognosis. As shown in Figures 6C–E, IL-2 (Th0),
IFNγ, and TNFα (Th1) transcript levels showed no statistically
significant association with NB prognosis. Surprisingly, IL-4
transcript levels were significantly associated with NB prognosis
(P = 0.05).

DISCUSSION
Neuroblastoma is the most common extra-cranial solid tumor
found in children and continues to have a poor prognosis in
cases of high-risk disease despite multimodal therapy (10–12).
Risk stratification is well defined in NB which predicts patient
outcome, but is also used to guide therapy. Risk stratification is
based on molecular, pathologic, and clinical findings, but there
are no immunologic parameters that are considered in defining
tumor risk (3). As immunotherapy in the form of either targeted
antibodies or checkpoint inhibitors is changing cancer treatment, understanding the immune environment could be critical
to both risk stratification, and application of immunotherapy.
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Figure 5 | Immunohistochemical analysis of leukocyte infiltration in neuroblastoma (NB). (A) Immunohistochemical staining of CD4 (brown) and CD45 (data not
shown) was performed on paraffin embedded NB tumor tissue at diagnostic biopsy from MYCN amplified high-risk, MYCN non-amplified high-risk, MYCN
non-amplified intermediate, and MYCN non-amplified low-risk tumors. The nuclei were counterstained with hematoxylin (blue). Tissue sections were imaged at ×100
original magnification. The association between CD4, CD45 expression, and MYCN amplification (B) and risk stratification (C) was determined by digital mean
density image analysis and the data are graphed. P-values in (C) were calculated with an unpaired Mann–Whitney test.

Figure 6 | Immunological mechanisms underlying the association between CD4 T cells and prognosis of neuroblastoma (NB) patients. (A) Top 10 significant
KEGG pathways enriched in NB samples with CD4hi. The normalized enrichment score normalized P-value and false discovery rate are displayed on the graphs.
(B) Gene set enrichment analysis enrichment plot showing significant enrichment of upregulated pathways (Fc gamma R-mediated phagocytosis; left, T cell
receptor; right) in NB samples with CD4hi. (C–E) Kaplan–Meier curves showing 5-year survival of NB patients according to their IL2 (C), IFNG, and TNFB (D), and
IL4 (E) gene expression normalized with the ratio of actin expression. The NB samples were divided into high- and low-groups based on their upper and lower
quartile of RNA-seq data. The hazard ratio and P-value displayed on the graphs are from the log-rank test and Gehan–Breslow–Wilcoxon method.

Frontiers in Immunology | www.frontiersin.org

7

November 2017 | Volume 8 | Article 1473

Zhang et al.

MYCN Repression of Cellular Immunity in NB

and NK cells, were significantly reduced in MYCN-amplified
tumors compared with non-amplified tumors. This observation
could have profound implications for the role of MYCN in NB
biology. MYCN drives many of the “hallmark” features of NB
that include tumorigenicity, cellular proliferation, and growth
as well as protein synthesis and altered cellular metabolism
(19, 20). The finding of repressed immune cell infiltrates in
MYCN amplified tumors implies a critical role for evading
immunity and may thus be a potential target for inducing immunogenicity. Indirect evidence is observed in the opsoclonus–
myoclonus syndrome associated with low or intermediate stage
NB. These tumors have profound T-cell infiltrates and are not
MYCN amplified (21–23). The OMS phenomenon is thought to
be an autoimmune effect and along with NB that spontaneously
regresses this tumor may be an ideal model for studying and
understanding tumor immunity as it relates to tumor biology
and prognosis. Of particular interest, recent findings indicate
that immunity plays a key role in tumor regression following
oncogene inactivation (24, 25). Experimentally, inactivation
of MYC in genetically engineered conditional mouse tumor
models, induced tumor regression when host immunity was
intact (26). CD4 helper cells were found to be critical to this
effect, suggesting that MYC oncogenicity occurs not only
through tumor-intrinsic mechanisms but also through hostdependent immune mechanisms. Our findings from patient
tumors confirm this phenomenon of MYCN amplified tumors
having a profound effect on cellular immunity.
In summary, our data show the association of MYCN amp
lification with repressed cellular immunity as well as the asso
ciation of infiltrating CD4 T cell transcripts with improved
prognosis in pediatric NB. These data illustrate the potential
role of MYCN in NB as a regulator of immune privilege and

characterizes the power of in silico analysis for understanding
cancer immunology and risk stratification.
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